Testoviron Testosterone Base Virilon Steroids For Breast Cancer CAS 58-22-0 - CAS 58-22-0

Testoviron Testosterone Base Virilon Steroids For Breast Cancer CAS 58-22-0 For Sale, Most Competitive Price, Fast Delivery, Custom Service, Wholesale Testoviron Testosterone Base Virilon Steroids For Breast Cancer CAS 58-22-0, Made in China, High Quality Products!, China cheap prodocuts, china suppliers Supplier, Manufacturer.
Testoviron Testosterone Base Virilon Steroids For Breast Cancer CAS 58-22-0

Testoviron Testosterone Base Virilon Steroids For Breast Cancer

?

1. Testosterone Base?Quick Detail
?

- - - -
Product name | Testosterone Base |
Other name | Testoviron; Oreton; Testex; Testoderm; Testred; Virilon; Testolent |
CAS register number | 58-22-0 |
EINECS | 200-370-5 |
Molecular formula | C19H28O2 |
Molecular weight | 288.42 |
Assay | 98% |
Appearance | White crystalline powder |
Usage | can be used as pharmaceutical material |
- - - -

?


2. Testosterone Base?Product description
Purpose: to promote the development of male genitalia and maintain their normal function, for disease-free testosterone replacement therapy, male menopause syndrome, impotence and other diseases Treatment, but also for women of functional uterine bleeding, dysmenorrhea, menorrhagia, aplastic anemia embolism. Usually used and its propionate ester derivatives of benzoic acid.?


Data presented on June 17, 2013, at the Endocrine Society& acute;s 95th Annual Meeting offered positive results regarding the use of testosterone to improve pain tolerance. Narcotic analgesics often lead to lower than normal testosterone levels in men, thus adding to their perceived pain, as well as contributing to symptoms like irritability and depression. The patents for two well-known and efficacious testosterone treatments.


Striant and Testoderm, have patent expirations of August 23, 2019 and November 10, 2019, respectively. The National Institutes of Health states that approximately 5 million American men do not produce enough of the hormone testosterone. Axiron is a highly profitable testosterone replacement therapy, with a patent expiration of February 19, 2017. The testosterone replacement Axiron generated over $48 million dollars in profit in 2011.


Coined “The Wittert Study”, after Gary Wittert who is the leader of this study, this novel study is banking on being the first of many to address the worldwide epidemic of type 2 diabetes using testosterone treatment as a preventative. The International Diabetes Federation has stated that the cost to treat type 2 diabetes worldwide now hovers at 471 billion dollars.


?
3. COA

- - - -
TEST ITEMS | SPECIFICATION | RESULTS |
Description | White or Almost White Crystalline Powder | white powder |
Identification | A.B. | Positive |
Assay | 97.0~103.0% | 99.3% |
Specific Rotation | ?+101°~+105° | +102.6° |
Loss On Drying | 1.0%max | 0.27% |
Melting Point | 153~157°C | 153.0~155.0°C |
Organic Volatile Impurities | meets the requirement | Conforms |
Related Substances | meets the requirement. | Conforms |
Residual Solvents | meets the requirement | Conforms |
Particle Size | 100% ≤ 20 microns | Conforms |
Conclusion | The specification conform with USP30 standard | ? |
- - - -

Get Quote

JCJ Logis Co.,ltd

Address: Qianjia Road ,Wuhan City ,Hubei Province, China, Shenzhen, Guangdong, China, 518000
Tel: 86-182-71829894
The company invests large fund and brains to R&D department to research fine chemical, biochemical, pharmaceutical & its intermediates products that fit the demand of the market. High level research group, advanced apparatus and good scientific atmosphere ensure the quality.

Related Products

Send A Message
*If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.